Enterobacterial analysis for the precise medical care (precision medicine) for diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease, and irritable bowel syndrome.

Enterobacterial analysis for the precise medical care (precision medicine) for diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease, and irritable bowel syndrome. - Enterobacterial analysis for the precise medical care (precision medicine).

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019486

Enrollment

175

Registered

2015-12-01

Start date

2016-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease (ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are diagnosed as follows: 1) Diabetes patients diagnosed based on the diagnostic criteria of the Japanese diabetes society 2015 2) NASH/NAFLD patients who are diagnosed based on the Medical treatment guide 2010 of NASH, NAFLD of Japanese liver society guidelines 3) IBS patients who are diagnosed based on ROME III criteria. 4) The patients diagnosed as ulcerative colitis and Crohn's disease based on the criteria of Japanese Ministry of Health, Specific disease intractable inflammation-related intestinal tract disorder research group.

Exclusion criteria

Exclusion criteria: 1) Re-registration example to the examination 2) The patients with surgical operation within 12 weeks 3) In addition, the patient who judged an arrangement to the examination if the medical attendant was inappropriate 4) The patients who have stoma.

Design outcomes

Primary

Measure	Time frame
Tendency of the enterobacterial flora of each disease compared to healthy control.	—

Countries

Japan

Contacts

Public ContactKazuhiko Uchiyama

Kyoto Prefectural University of Medicinea Molecular Gastroenterology and Hepatology

k-uchi@koto.kpu-m.ac.jp075-251-5519

Outcome results